Erik Nord
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Erik Nord has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Paul Menzel
Pacific Lutheran University, Tacoma, USA
3 shared publicationsJeff Richardson
Monash University, Melbourne, Australia
2 shared publications- Jeff Richardson
Monash University
2 shared publications Peter Ubel
University of Michigan, Ann Arbor, USA
2 shared publicationsRune Johansen
Norwegian Institute of Public Health, P.O. Box 4404, N-0403 Oslo, Norway
2 shared publicationsAnja Undrum Enge
Norwegian Institute of Public Health, The University of Oslo, Oslo, Norway
1 shared publication
Latest Publications
- 29 June 2019
- Published by Wiley in International Journal of Cancer
- Vol. 146 (8) , 2104-2112
Quality‐of‐life effects of screening mammography in Norway
Mammography screening may save women from dying of breast cancer, although it has not been shown to reduce all‐cause mortality. Screening also leads to overdiagnosis and many false positive mammograms aggravating women's quality‐of‐life. Quality adjusted life years (QALY) analyses of mammography screening have so far, calculated life years gained assuming that all prevented breast cancer deaths translate into a reduction in all‐cause mortality. We calculated net QALYs in two hypothesized cohorts of 100,000 Norwegian women; one screened biennially from age 50 to 69 years and one not screened. We followed both cohorts to age 85 years. We used EQ‐5D and an alternative equity weighted QALY instrument to estimate utility losses. In the screening cohort, we assumed 20% false positive tests during screening, different levels of overdiagnosis (20–75%) and different levels of breast cancer mortality reduction (10–30%). We assumed that reductions in breast cancer mortality only to a limited extent (20, 50 or 80%), resulted in reductions in all‐cause mortality. We calculated both undiscounted and discounted (4%) QALYs. Assuming that 50% of the reduction in breast cancer mortality translated to a reduction in all‐cause mortality and using estimated levels of benefits and harms in modern screening programs (50–75% overdiagnosis and 10% reduction in breast cancer mortality), undiscounted equity weighted QALY loss varied from 437 to 875 per 100,000 women. Using the levels of benefit and harms as reported in 30–40 years old randomized trials (30% overdiagnosis and 15% reduction in breast cancer mortality), undiscounted equity weighted QALY gain was 535 per 100,000. Net QALY in modern mammography screening in Norway is negative. Results could also be representative for Sweden, Denmark, UK and the US.
- 29 June 2019
- Published by Wiley in International Journal of Cancer
- Vol. 146 (8) , 2104-2112
Quality‐of‐life effects of screening mammography in Norway
Mammography screening may save women from dying of breast cancer, although it has not been shown to reduce all‐cause mortality. Screening also leads to overdiagnosis and many false positive mammograms aggravating women's quality‐of‐life. Quality adjusted life years (QALY) analyses of mammography screening have so far, calculated life years gained assuming that all prevented breast cancer deaths translate into a reduction in all‐cause mortality. We calculated net QALYs in two hypothesized cohorts of 100,000 Norwegian women; one screened biennially from age 50 to 69 years and one not screened. We followed both cohorts to age 85 years. We used EQ‐5D and an alternative equity weighted QALY instrument to estimate utility losses. In the screening cohort, we assumed 20% false positive tests during screening, different levels of overdiagnosis (20–75%) and different levels of breast cancer mortality reduction (10–30%). We assumed that reductions in breast cancer mortality only to a limited extent (20, 50 or 80%), resulted in reductions in all‐cause mortality. We calculated both undiscounted and discounted (4%) QALYs. Assuming that 50% of the reduction in breast cancer mortality translated to a reduction in all‐cause mortality and using estimated levels of benefits and harms in modern screening programs (50–75% overdiagnosis and 10% reduction in breast cancer mortality), undiscounted equity weighted QALY loss varied from 437 to 875 per 100,000 women. Using the levels of benefit and harms as reported in 30–40 years old randomized trials (30% overdiagnosis and 15% reduction in breast cancer mortality), undiscounted equity weighted QALY gain was 535 per 100,000. Net QALY in modern mammography screening in Norway is negative. Results could also be representative for Sweden, Denmark, UK and the US.
- Open Access
- 30 April 2018
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 2 (4) , 357-358
Including Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary
- 30 April 2018
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 2 (4) , 357-358
Open AccessIncluding Future Consumption and Production in Economic Evaluation of Interventions that Save Life-Years: Commentary
- 3 March 2017
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 19 (2) , 267-275
Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies
The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of and societal willingness to pay for health technologies, gains in quality of life and length of life are prima facie separate criteria that need not be put together in a single concept. A focus on costs per QALY can also be counterproductive. One reason is that the QALY does not capture well the value of interventions in patients with reduced potentials for health and thus different reference points. Another reason is a need to separate losses of length of life and losses of quality of life when it comes to judging the strength of moral claims on resources in patients of different ages. An alternative to the cost-per-QALY approach is outlined, consisting in the development of two bivariate value tables that may be used in combination to estimate maximum cost acceptance for given units of treatment—for instance a surgical procedure, or 1 year of medication—rather than for ‘obtaining one QALY.’ The approach is a follow-up of earlier work on ‘cost value analysis.’ It draws on work in the QALY field insofar as it uses health state values established in that field. But it does not use these values to weight life years and thus avoids devaluing gained life years in people with chronic illness or disability. Real tables of the kind proposed could be developed in deliberative processes among policy makers and serve as guidance for decision makers involved in health technology assessment and appraisal.
- 3 March 2017
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 19 (2) , 267-275
Beyond QALYs: Multi-criteria based estimation of maximum willingness to pay for health technologies
The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of and societal willingness to pay for health technologies, gains in quality of life and length of life are prima facie separate criteria that need not be put together in a single concept. A focus on costs per QALY can also be counterproductive. One reason is that the QALY does not capture well the value of interventions in patients with reduced potentials for health and thus different reference points. Another reason is a need to separate losses of length of life and losses of quality of life when it comes to judging the strength of moral claims on resources in patients of different ages. An alternative to the cost-per-QALY approach is outlined, consisting in the development of two bivariate value tables that may be used in combination to estimate maximum cost acceptance for given units of treatment—for instance a surgical procedure, or 1 year of medication—rather than for ‘obtaining one QALY.’ The approach is a follow-up of earlier work on ‘cost value analysis.’ It draws on work in the QALY field insofar as it uses health state values established in that field. But it does not use these values to weight life years and thus avoids devaluing gained life years in people with chronic illness or disability. Real tables of the kind proposed could be developed in deliberative processes among policy makers and serve as guidance for decision makers involved in health technology assessment and appraisal.
- 29 March 2016
- Published by Oxford University Press (OUP) in Public Health Ethics
- p. phw008
Public Values for Health States Versus Societal Valuations of Health Improvements: A Critique of Dan Hausman’s ‘Valuing Health’
Daniel Hausman’s book ‘Valuing Health’ is a valuable contribution to our understanding of QALYs and DALYs and to moving health economics to adopting a broader perspective than that taken in conventional cost-effectiveness analysis. Hausman’s attempt at constructing a public value table for health states without having recourse to data from population preferences studies is also a fascinating read. But I have serious concerns about his resulting table. Hausman’s views on which dimensions of health a benevolent liberal state should care about are essentially not different from what has long been emphasized in health economists’ work on valuations of health outcomes. His table would have been helpful as a sketch if it was the first attempt in health economics to quantify numerically the societal value of different types and degrees of health improvement. But research in the field has gone far beyond that. Multi-attribute utility instruments with much more accurate health classification systems than Hausman’s sketch are now at hand. Available also are models of societal valuations of QALYs that (i) are broadly consistent with general population values, (ii) incorporate wider concerns than Hausman’s table does and (iii) do not have the questionable numerical properties that characterize Hausman’s sketch.
- 29 March 2016
- Published by Oxford University Press (OUP) in Public Health Ethics
- p. phw008
Public Values for Health States Versus Societal Valuations of Health Improvements: A Critique of Dan Hausman’s ‘Valuing Health’
Daniel Hausman’s book ‘Valuing Health’ is a valuable contribution to our understanding of QALYs and DALYs and to moving health economics to adopting a broader perspective than that taken in conventional cost-effectiveness analysis. Hausman’s attempt at constructing a public value table for health states without having recourse to data from population preferences studies is also a fascinating read. But I have serious concerns about his resulting table. Hausman’s views on which dimensions of health a benevolent liberal state should care about are essentially not different from what has long been emphasized in health economists’ work on valuations of health outcomes. His table would have been helpful as a sketch if it was the first attempt in health economics to quantify numerically the societal value of different types and degrees of health improvement. But research in the field has gone far beyond that. Multi-attribute utility instruments with much more accurate health classification systems than Hausman’s sketch are now at hand. Available also are models of societal valuations of QALYs that (i) are broadly consistent with general population values, (ii) incorporate wider concerns than Hausman’s table does and (iii) do not have the questionable numerical properties that characterize Hausman’s sketch.
- Open Access
- 1 November 2015
- Published by Elsevier in The Lancet Global Health
- Vol. 3 (11) , e661-e662
Uncertainties about disability weights for the Global Burden of Disease study
- 1 November 2015
- Published by Elsevier in The Lancet Global Health
- Vol. 3 (11) , e661-e662
Open AccessUncertainties about disability weights for the Global Burden of Disease study
- Open Access
- 22 September 2015
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 135 (17) , 1529-30
Re: Alder og alvor
22.09.2015: Brev til redaktøren - Bjarne Robberstads drøfting av alder og alvor (1) er teknisk interessant, men jeg mener han skaper forvirring ved ikke å skille mellom hva et godt etablert uttrykk som «en tilstands alvorlighet» betyr i medisin og hvilken vekt man kan ønske å legge på ulike hensyn ved prioritering.
- 22 September 2015
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 135 (17) , 1529-30
Open AccessRe: Alder og alvor
22.09.2015: Brev til redaktøren - Bjarne Robberstads drøfting av alder og alvor (1) er teknisk interessant, men jeg mener han skaper forvirring ved ikke å skille mellom hva et godt etablert uttrykk som «en tilstands alvorlighet» betyr i medisin og hvilken vekt man kan ønske å legge på ulike hensyn ved prioritering.
- Open Access
- 11 November 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (21) , 2062-5
Markov-modellering
Helseøkonomiske analyser brukes til å beskrive forholdet mellom kostnader og helsegevinster ved ulike behandlinger og forebyggende tiltak. Analysene er ment å være til hjelp ved prioritering. I analysene søker man å ta høyde for at sykdomsforløp varierer over tid og at ressursbruk og effekter varierer mellom individer. Markov-modellering er en vanlig måte å ivareta denne variasjonen på. Her gis et konkret eksempel på hvordan slik modellering gjøres.
- 11 November 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (21) , 2062-5
Open AccessMarkov-modellering
Helseøkonomiske analyser brukes til å beskrive forholdet mellom kostnader og helsegevinster ved ulike behandlinger og forebyggende tiltak. Analysene er ment å være til hjelp ved prioritering. I analysene søker man å ta høyde for at sykdomsforløp varierer over tid og at ressursbruk og effekter varierer mellom individer. Markov-modellering er en vanlig måte å ivareta denne variasjonen på. Her gis et konkret eksempel på hvordan slik modellering gjøres.
- 1 June 2014
- Published by Elsevier in Health Policy
- Vol. 116 (2-3) , 281-288
Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY
- 1 June 2014
- Published by Elsevier in Health Policy
- Vol. 116 (2-3) , 281-288
Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY
- Open Access
- 29 April 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (8) , 809
Re: Sjeldenhet – eget kriterium ved prioritering?
- 29 April 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (8) , 809
Open AccessRe: Sjeldenhet – eget kriterium ved prioritering?
- 22 March 2014
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 16 (3) , 313-328
Transforming EQ-5D utilities for use in cost–value analysis of health programs
In a number of jurisdictions there is increasing interest in incorporating concerns for fairness in models for economic evaluation of health interventions. Cost–value analysis is a name for evaluations with such a broader aim. The most widely held concern for fairness is a concern for the worse off, i.e. the idea that severity of illness should count in determining priorities. In economic evaluations of improvements in health-related quality of life this concern may be taken into account by replacing conventional health state utilities with societal values for health states that are characterised by strong upper end compression and decreasing marginal value of utility gains. We review evidence on the strength of concerns for the worse off—measured at the cardinal level—in 15 articles published in peer-reviewed journals in the time period 1978–2010, with reports from altogether 20 individual studies in nine different countries. We report 116 individual observations of paired comparisons of utility improvements with different start levels. Concerns for severity show up quite strongly across countries, sample types and question framings. By means of regression analyses we fit a societal value function to the data that has the property of decreasing marginal value of utility gains. Using the central tendency in the data we present two plausible transformations of EQ-5D utilities into societal values that reflect concerns for the worse off.
- 22 March 2014
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 16 (3) , 313-328
Transforming EQ-5D utilities for use in cost–value analysis of health programs
In a number of jurisdictions there is increasing interest in incorporating concerns for fairness in models for economic evaluation of health interventions. Cost–value analysis is a name for evaluations with such a broader aim. The most widely held concern for fairness is a concern for the worse off, i.e. the idea that severity of illness should count in determining priorities. In economic evaluations of improvements in health-related quality of life this concern may be taken into account by replacing conventional health state utilities with societal values for health states that are characterised by strong upper end compression and decreasing marginal value of utility gains. We review evidence on the strength of concerns for the worse off—measured at the cardinal level—in 15 articles published in peer-reviewed journals in the time period 1978–2010, with reports from altogether 20 individual studies in nine different countries. We report 116 individual observations of paired comparisons of utility improvements with different start levels. Concerns for severity show up quite strongly across countries, sample types and question framings. By means of regression analyses we fit a societal value function to the data that has the property of decreasing marginal value of utility gains. Using the central tendency in the data we present two plausible transformations of EQ-5D utilities into societal values that reflect concerns for the worse off.